denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
N.Schotten, N.
NA, F.
1965 - Donor Lymphocyte Infusion in Patients with Thalassemia Major Who Have Mixed Chimerism Following Allogeneic Stem Cell Transplant
2620 - Prognostic Significance of Immunophenotypic Composition of B Cell Acute Lymphoblastic Leukemia at Diagnosis: A Novel Immunophenotype Based Risk Score
3219 - Outcome of Allogeneic Stem Cell Transplantation for Thalassemia Major in India
3732 - Adult Acute Lymphoblastic Leukemia: A Cost Effective Strategy and Limitations of Intensification of Therapy in India
3758 - Coagulopathy in Acute Promyelocytic Leukemia: Strategies to Improve Assessment of Hemostatic Risk
2620 - Prognostic Significance of Immunophenotypic Composition of B Cell Acute Lymphoblastic Leukemia at Diagnosis: A Novel Immunophenotype Based Risk Score
3219 - Outcome of Allogeneic Stem Cell Transplantation for Thalassemia Major in India
3732 - Adult Acute Lymphoblastic Leukemia: A Cost Effective Strategy and Limitations of Intensification of Therapy in India
3758 - Coagulopathy in Acute Promyelocytic Leukemia: Strategies to Improve Assessment of Hemostatic Risk
Na, I. K.
858 - Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients
2012 - Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
2012 - Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
Nabhan, C.
719 - Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study
881 - Toxicity of Maintenance Rituximab in Older Adults with Non-Hodgkin Lymphoma
1500 - Risk Factors for CNS Relapse Among Patients with DLBCL Treated with EPOCH-R
3284 - Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study
4483 - Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry
881 - Toxicity of Maintenance Rituximab in Older Adults with Non-Hodgkin Lymphoma
1500 - Risk Factors for CNS Relapse Among Patients with DLBCL Treated with EPOCH-R
3284 - Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study
4483 - Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry
Nabhani, S.
Nabinger, S. C.
Nachbaur, D.
Nachman, P. H.
Nachreiner, T.
Nachtkamp, K.
Nadanaciva, S.
Nadarajah, N.
1356 - A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene
1645 - TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition
1646 - Myelodysplastic Syndrome Patients Show Mutation-Specific DNA Methylation Patterns
1721 - Modulation of the Clonal Composition in Relapsed CLL: A Study Based on Targeted Deep-Sequencing of ATM, BIRC3, NOTCH1, POT1, SF3B1, SAMHD1 and TP53
2578 - AML with RUNX1 Mutations and Loss of RUNX1 Wild-Type - a Distinct Subset?
2610 - Three Steps to the Diagnosis of Adult Ph-like ALL
2841 - Two Novel Distinct Subtypes of Myeloid Neoplasms Molecularly Associated with Histone H3K36 Methylations
2849 - Significance Assessment of Mutations in MDS Patients Using Publicly Available Databases: A Study with 944 Samples and 6 Most Significantly Mutated Genes
3846 - Molecular Characterization of Philadelphia Chromosome Positive Acute Myeloid Leukemia - New Provisional Entity?
4111 - Accumulation of Somatic Mutations As a Function of Aging: A Study on 4843 TET2 Mutated Patients in Comparison to Their Respective SNP Pattern
1645 - TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition
1646 - Myelodysplastic Syndrome Patients Show Mutation-Specific DNA Methylation Patterns
1721 - Modulation of the Clonal Composition in Relapsed CLL: A Study Based on Targeted Deep-Sequencing of ATM, BIRC3, NOTCH1, POT1, SF3B1, SAMHD1 and TP53
2578 - AML with RUNX1 Mutations and Loss of RUNX1 Wild-Type - a Distinct Subset?
2610 - Three Steps to the Diagnosis of Adult Ph-like ALL
2841 - Two Novel Distinct Subtypes of Myeloid Neoplasms Molecularly Associated with Histone H3K36 Methylations
2849 - Significance Assessment of Mutations in MDS Patients Using Publicly Available Databases: A Study with 944 Samples and 6 Most Significantly Mutated Genes
3846 - Molecular Characterization of Philadelphia Chromosome Positive Acute Myeloid Leukemia - New Provisional Entity?
4111 - Accumulation of Somatic Mutations As a Function of Aging: A Study on 4843 TET2 Mutated Patients in Comparison to Their Respective SNP Pattern
Nadeau, S.
Nadella, D.
Nademanee, A. P.
519 - Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT
522 - Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation
1961 - Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation
3172 - Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse
3179 - Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?
522 - Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation
1961 - Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation
3172 - Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse
3179 - Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?
Nadeu, F.
Nadworny, S.
Næss, I. A.
Naeve, D.
Nagae, G.
Nagafuji, K.
Nagai, K.
1759 - Long Non-Coding RNA MALAT1 Is Associated with the Progression of Multiple Myeloma and Induced By Cellular Stress
2245 - Th1 Polarization of Cytokine and Cytokine Receptor Polymorphisms Affect the Susceptibility and Severity of ITP
3013 - Loop Regulation Between microRNAs and Epigenetics Underlie microRNA Dysregulation in Multiple Myeloma and Is Associated with the Disease Progression
2245 - Th1 Polarization of Cytokine and Cytokine Receptor Polymorphisms Affect the Susceptibility and Severity of ITP
3013 - Loop Regulation Between microRNAs and Epigenetics Underlie microRNA Dysregulation in Multiple Myeloma and Is Associated with the Disease Progression
Nagamachi, A.
Nagamura-Inoue, T.
Naganuma, E.
Nagao, Y.
Nagarwala, Y.
1853 - Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)
4229 - Clinical Outcomes of Patients with Newly Diagnosed Multiple Myeloma Receiving Triplet Therapy in the Connect MM® Disease Registry
4229 - Clinical Outcomes of Patients with Newly Diagnosed Multiple Myeloma Receiving Triplet Therapy in the Connect MM® Disease Registry
Nagarwala, Y.
Nagasawa, T.
Nagashima, T.
1759 - Long Non-Coding RNA MALAT1 Is Associated with the Progression of Multiple Myeloma and Induced By Cellular Stress
2245 - Th1 Polarization of Cytokine and Cytokine Receptor Polymorphisms Affect the Susceptibility and Severity of ITP
3013 - Loop Regulation Between microRNAs and Epigenetics Underlie microRNA Dysregulation in Multiple Myeloma and Is Associated with the Disease Progression
2245 - Th1 Polarization of Cytokine and Cytokine Receptor Polymorphisms Affect the Susceptibility and Severity of ITP
3013 - Loop Regulation Between microRNAs and Epigenetics Underlie microRNA Dysregulation in Multiple Myeloma and Is Associated with the Disease Progression
Nagata, S.
Nagata, Y.
113 - Frequent Activating Somatic Alterations in T-Cell Receptor / NF-κb Signaling in Adult T-Cell Leukemia/Lymphoma
709 - Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing
711 - Impact of Somatic Mutations on Outcome in Patients with MDS after Stem-Cell Transplantation
1646 - Myelodysplastic Syndrome Patients Show Mutation-Specific DNA Methylation Patterns
2643 - Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Leukemia/Lymphoma
2687 - Genetic Basis of Primary Central Nervous System Lymphoma
2841 - Two Novel Distinct Subtypes of Myeloid Neoplasms Molecularly Associated with Histone H3K36 Methylations
2843 - Genetic Predispositions to Myeloid Neoplasms Caused By Germline DDX41 Mutations
3882 - Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma
709 - Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing
711 - Impact of Somatic Mutations on Outcome in Patients with MDS after Stem-Cell Transplantation
1646 - Myelodysplastic Syndrome Patients Show Mutation-Specific DNA Methylation Patterns
2643 - Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Leukemia/Lymphoma
2687 - Genetic Basis of Primary Central Nervous System Lymphoma
2841 - Two Novel Distinct Subtypes of Myeloid Neoplasms Molecularly Associated with Histone H3K36 Methylations
2843 - Genetic Predispositions to Myeloid Neoplasms Caused By Germline DDX41 Mutations
3882 - Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma
Nagel, S.
NageswaraRao, A.
Nagle, S. J.
2694 - Brentuximab Vedotin in Combination with Multi-Agent Chemotherapy Is Well Tolerated and Shows Promising Activity As Frontline Treatment for Primary Mediastinal B-Cell Lymphoma
2701 - Long Term Outcomes of Rituximab, Temozolamide, and High-Dose Methotrexate for Lymphoma Involving the Central Nervous System
2701 - Long Term Outcomes of Rituximab, Temozolamide, and High-Dose Methotrexate for Lymphoma Involving the Central Nervous System
Nagler, A.
63 - Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT
153 - Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Inherited or Acquired Bone Marrow Failure Disorders: A Report from Eurocord, Cord Blood Committee (CBC-CTIWP) and Severe Aplastic Anemia Working Party (SAAWP) of the European Group of Blood and Bone Marrow Transplantation (EBMT)
155 - Reduced-Intensity Versus Myeloablative Conditioning for Unrelated Cord Blood Transplantation in Adults with Acute Leukemia: A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Group for Blood and Marrow Transplantation
196 - Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT
399 - HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
827 - An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study
863 - Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT
926 - Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission : Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT
928 - Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers
1661 - Phase 3, Placebo-Controlled, ASPIRE Study (TRC114968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability
1889 - Anti-Human T-Lymphocyte Immunoglobulin (ATG)-Induced T Regulatory Cells and Their Soluble Factors Suppress T Cell Proliferation: Potential Role in Allogeneic Stem Cell Transplantation
1942 - The Combination of Cyclosporine and Mycophenolate Mofetil Is Less Effective Than Cyclosporine and Methotrexate in the Prevention of Acute Graft-Versus Host Disease after Allogeneic Stem Cell Transplantation from Unrelated Donors
1958 - Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT
2021 - Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and 17p Abnormalities in First Complete Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT)
2546 - The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia
2798 - Pathogenesis of Ponatinib Associated Vascular Disease in Chronic Myeloid Leukemia: An in Vitro Study
3105 - Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT
3110 - The Risk of Sinusoidal Obstruction Syndrome (SOS) in Allogeneic Hematopoietic Stem Cell Transplantation after Prior Gemtuzumab Ozogamicin Treatment: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
3111 - Impact of HLA of Winning Cord Blood Unit on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee Cellular Therapy and Immunobiology Working Party and the Acute Leukemia Working Party of the EBMT
3202 - Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT
3211 - A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT
3216 - Comparison of Matched/Mismatched Unrelated Donor Stem Cell Transplantation to Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
3223 - The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes
3226 - Evaluation of the Impact of Non-Inherited Maternal Antigens on the Outcome of HLA Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for Hematological Malignancies on Behalf of the ALWP of the EBMT and the CIBMTR
3246 - Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study
4218 - Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease
4316 - Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
4346 - Incidence, Risk Factors, Treatment and Outcome of Isolated Extramedullary Relapse after Allogeneic Stem Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome
4361 - Brentuximab Vedotin in Combination with Donor Lymphocyte Infusion for Patients with Hodgkin Lymphoma Relapsing after Allogeneic Stem Cell Transplantation
4364 - Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT)
4390 - Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT
153 - Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Inherited or Acquired Bone Marrow Failure Disorders: A Report from Eurocord, Cord Blood Committee (CBC-CTIWP) and Severe Aplastic Anemia Working Party (SAAWP) of the European Group of Blood and Bone Marrow Transplantation (EBMT)
155 - Reduced-Intensity Versus Myeloablative Conditioning for Unrelated Cord Blood Transplantation in Adults with Acute Leukemia: A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Group for Blood and Marrow Transplantation
196 - Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT
399 - HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
827 - An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study
863 - Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT
926 - Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission : Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT
928 - Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers
1661 - Phase 3, Placebo-Controlled, ASPIRE Study (TRC114968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability
1889 - Anti-Human T-Lymphocyte Immunoglobulin (ATG)-Induced T Regulatory Cells and Their Soluble Factors Suppress T Cell Proliferation: Potential Role in Allogeneic Stem Cell Transplantation
1942 - The Combination of Cyclosporine and Mycophenolate Mofetil Is Less Effective Than Cyclosporine and Methotrexate in the Prevention of Acute Graft-Versus Host Disease after Allogeneic Stem Cell Transplantation from Unrelated Donors
1958 - Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT
2021 - Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and 17p Abnormalities in First Complete Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT)
2546 - The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia
2798 - Pathogenesis of Ponatinib Associated Vascular Disease in Chronic Myeloid Leukemia: An in Vitro Study
3105 - Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT
3110 - The Risk of Sinusoidal Obstruction Syndrome (SOS) in Allogeneic Hematopoietic Stem Cell Transplantation after Prior Gemtuzumab Ozogamicin Treatment: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
3111 - Impact of HLA of Winning Cord Blood Unit on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee Cellular Therapy and Immunobiology Working Party and the Acute Leukemia Working Party of the EBMT
3202 - Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT
3211 - A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT
3216 - Comparison of Matched/Mismatched Unrelated Donor Stem Cell Transplantation to Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
3223 - The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes
3226 - Evaluation of the Impact of Non-Inherited Maternal Antigens on the Outcome of HLA Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for Hematological Malignancies on Behalf of the ALWP of the EBMT and the CIBMTR
3246 - Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study
4218 - Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease
4316 - Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
4346 - Incidence, Risk Factors, Treatment and Outcome of Isolated Extramedullary Relapse after Allogeneic Stem Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome
4361 - Brentuximab Vedotin in Combination with Donor Lymphocyte Infusion for Patients with Hodgkin Lymphoma Relapsing after Allogeneic Stem Cell Transplantation
4364 - Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT)
4390 - Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT
Nagorsen, D.
680 - Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
789 - Expression of Novel Immune Checkpoint Molecules PVR and PVRL2 Confers a Negative Prognosis to Patients with Acute Myeloid Leukemia and Their Blockade Augments T-Cell Mediated Lysis of AML Cells Alone or in Combination with the BiTE® Antibody Construct AMG 330
789 - Expression of Novel Immune Checkpoint Molecules PVR and PVRL2 Confers a Negative Prognosis to Patients with Acute Myeloid Leukemia and Their Blockade Augments T-Cell Mediated Lysis of AML Cells Alone or in Combination with the BiTE® Antibody Construct AMG 330
Nagoshi, H.
2500 - A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management
4182 - The Epigenetic Repression of Mir-375 Is the Dominant Mechanism for the Constitutive Activation of PDPK1/RSK2 Signaling Axis in Multiple Myeloma
4182 - The Epigenetic Repression of Mir-375 Is the Dominant Mechanism for the Constitutive Activation of PDPK1/RSK2 Signaling Axis in Multiple Myeloma
Nagourney, R.
Nagpal, S.
Nagy, Z.
Nahas, M.
1422 - Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL
2651 - Predictive and Prognostic Significance of Comprehensive Genomic Profiling in Patients with Diffuse Large B-Cell Lymphoma
3898 - Comprehensive Genomic Profiling (CGP) of Angioimmunoblastic T-Cell Lymphoma (AITL) to Prospectively Inform Diagnosis and Clinical Management
2651 - Predictive and Prognostic Significance of Comprehensive Genomic Profiling in Patients with Diffuse Large B-Cell Lymphoma
3898 - Comprehensive Genomic Profiling (CGP) of Angioimmunoblastic T-Cell Lymphoma (AITL) to Prospectively Inform Diagnosis and Clinical Management
Nahas, M. R.
Nahi, H.
26 - Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)
29 - Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
3047 - The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex
29 - Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
3047 - The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex
Nahum, O.
Nai, A.
Naik, R. P.
70 - Association of Hemoglobin S and C Traits with Kidney Disease in African Americans in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study
3405 - Metabolic Syndrome Risk Among Adults Living with Sickle Cell Disease
- Sickle Cell Trait Diagnosis: Clinical and Social Implications
3405 - Metabolic Syndrome Risk Among Adults Living with Sickle Cell Disease
- Sickle Cell Trait Diagnosis: Clinical and Social Implications
Naik, S.
Naim, A. B.
2813 - Disease and Clinical Characteristics of Patients with Polycythemia Vera: An Early View of the Reveal Study
4070 - The Effect of Ruxolitinib on White Blood Cell Counts in Patients with Polycythemia Vera: Results from the RESPONSE Trial
4077 - Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States
4084 - Self-Reported Quality-of-Life Impairment and Productivity Loss in Patients with Polycythemia Vera: Early Patient-Reported Outcomes Assessment from the REVEAL Study
4070 - The Effect of Ruxolitinib on White Blood Cell Counts in Patients with Polycythemia Vera: Results from the RESPONSE Trial
4077 - Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States
4084 - Self-Reported Quality-of-Life Impairment and Productivity Loss in Patients with Polycythemia Vera: Early Patient-Reported Outcomes Assessment from the REVEAL Study
Naina, H. V.
Nair, J. R.
Nair, P. M.
Nair, P. R.
Nair, S.
Nair, S.
Nairz, M.
Najjar, A.
Nakabayashi, J.
Nakagami, Y.
Nakagawa, M. M.
Nakagawa, M.
Nakagawa, N.
Nakahata, T.
Nakahata, T.
Nakajima, H.
Nakamae, H.
Nakamae, M.
Nakamaki, T.
113 - Frequent Activating Somatic Alterations in T-Cell Receptor / NF-κb Signaling in Adult T-Cell Leukemia/Lymphoma
709 - Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing
2643 - Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Leukemia/Lymphoma
2841 - Two Novel Distinct Subtypes of Myeloid Neoplasms Molecularly Associated with Histone H3K36 Methylations
2843 - Genetic Predispositions to Myeloid Neoplasms Caused By Germline DDX41 Mutations
3882 - Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma
709 - Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing
2643 - Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Leukemia/Lymphoma
2841 - Two Novel Distinct Subtypes of Myeloid Neoplasms Molecularly Associated with Histone H3K36 Methylations
2843 - Genetic Predispositions to Myeloid Neoplasms Caused By Germline DDX41 Mutations
3882 - Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma
Nakamoto-Matsubara, R.
Nakamura, D.
Nakamura, H.
Nakamura, K.
Nakamura, K.
Nakamura, M.
Nakamura, N.
Nakamura, N.
Nakamura, N.
Nakamura, R.
Nakamura, S.
1097 - Genetic Analysis of Von Willebrand Disease By Using the Exome Sequencing Approach
3886 - Prognostic Impact of MUM1/IRF4 Expression in Burkitt Lymphoma (BL): A Reappraisal of 89 BL Patients in Japan
3911 - Prognostic Significance of EBV Association in Diffuse Large B-Cell Lymphoma in the Rituximab Era
3886 - Prognostic Impact of MUM1/IRF4 Expression in Burkitt Lymphoma (BL): A Reappraisal of 89 BL Patients in Japan
3911 - Prognostic Significance of EBV Association in Diffuse Large B-Cell Lymphoma in the Rituximab Era
Nakamura, S.
Nakamura, T.
Nakamura, Y.
Nakane, T.
Nakanishi, T.
Nakano, N.
Nakao, S.
1168 - Evidence That T Cells Specific for Non-Hematopoietic Cells Trigger the Development of Acquired Aplastic Anemia
1215 - A Cure for Paroxysmal Nocturnal Hemoglobinuria Using Molecular Targeted Therapy Specific to a Driver Mutation
1782 - A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation
1788 - Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation
2409 - Auto-Reactive Glycosyl-Phosphatidyl-Inositol (GPI) Specific T Cells Are Present in Most Patients with Idiopathic Aplastic Anemia (IAA)
2415 - Generation of Ips Cell-Derived Hematopoietic Progenitor Cells from Patients with Acquired Aplastic Anemia Harboring Copy Number Neutral Loss of Heterozygosity of the Short Arm of Chromosome 6
2418 - Evidence for a Common Immune Pathophysiology in Acquired Aplastic Anemia and Ulcerative Colitis
1215 - A Cure for Paroxysmal Nocturnal Hemoglobinuria Using Molecular Targeted Therapy Specific to a Driver Mutation
1782 - A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation
1788 - Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation
2409 - Auto-Reactive Glycosyl-Phosphatidyl-Inositol (GPI) Specific T Cells Are Present in Most Patients with Idiopathic Aplastic Anemia (IAA)
2415 - Generation of Ips Cell-Derived Hematopoietic Progenitor Cells from Patients with Acquired Aplastic Anemia Harboring Copy Number Neutral Loss of Heterozygosity of the Short Arm of Chromosome 6
2418 - Evidence for a Common Immune Pathophysiology in Acquired Aplastic Anemia and Ulcerative Colitis
Nakar, C. T.
Nakaseko, C.
712 - Combinatorial Epigenetic Aberration Propagates in Myelodysplastic Syndrome in the Setting of Concurrent Loss of Tet2 and Ezh2
859 - Donor Cell-Derived Hematologic Malignancy: A Survey of Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation
2024 - Prognostic Impact of Cytogenetic Abnormalities in Adult Patients with Philadelphia-Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL) Who Underwent Allogeneic Stem Cell Transplant (allo-SCT)
3640 - Diverse Role of DNA Hypermethylation in Reduced Expression of Tumor Suppressor NR4A3 in Acute Myeloid Leukemia
4032 - Switching to Nilotinib Are Associated with Deeper Molecular Responses in Chronic Myeloid Leukemia with Persistent Residual Disease on Long-Term Imatinib Therapy: STAT1 Trial in Japan
859 - Donor Cell-Derived Hematologic Malignancy: A Survey of Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation
2024 - Prognostic Impact of Cytogenetic Abnormalities in Adult Patients with Philadelphia-Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL) Who Underwent Allogeneic Stem Cell Transplant (allo-SCT)
3640 - Diverse Role of DNA Hypermethylation in Reduced Expression of Tumor Suppressor NR4A3 in Acute Myeloid Leukemia
4032 - Switching to Nilotinib Are Associated with Deeper Molecular Responses in Chronic Myeloid Leukemia with Persistent Residual Disease on Long-Term Imatinib Therapy: STAT1 Trial in Japan
Nakashima, M.
Nakashima, Y.
Nakatani, T.
Nakatsuka, R.
Nakauchi, H.
1649 - Srsf2 P95H Mutation Causes Impaired Stem Cell Repopulation and Hematopoietic Differentiation in Mice
1867 - Protection of Transplanted Hematopoietic Stem Cells from Inflammatory Recipient Marrow Environment through Specific TNF-α Signal Blockade
3071 - Proof of Benefit in Multiple-Cord Blood Transplantation Evidenced By Early Hematopoietic Reconstitution
1867 - Protection of Transplanted Hematopoietic Stem Cells from Inflammatory Recipient Marrow Environment through Specific TNF-α Signal Blockade
3071 - Proof of Benefit in Multiple-Cord Blood Transplantation Evidenced By Early Hematopoietic Reconstitution
Nakayama, H.
Nakayama, M.
Nakayama, M.
Nakayama, T.
Nakazato, T.
Nakazawa, C. Y.
Nakazawa, Y.
Nakitandwe, J.
Nakjang, S.
Nakken, S.
Nakorn, T. N.
3026 - Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma
4230 - Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment
4230 - Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment
Naldini, L.
Nalepa, G.
1211 - Impaired Spindle Assembly Checkpoint In Vivo Promotes MDS/AML in a Novel Mouse Model of Fanconi Anemia
3612 - Kinome-Wide shRNA Screen Reveals Functional Connections Between FANCA, Mitotic Centrosomes and the Spindle Assembly Checkpoint Tumor Suppressor Pathways
3620 - A Novel Splice Site Mutation in the 5'UTR of GATA1 resulting in Abnormal Hematopoiesis
3612 - Kinome-Wide shRNA Screen Reveals Functional Connections Between FANCA, Mitotic Centrosomes and the Spindle Assembly Checkpoint Tumor Suppressor Pathways
3620 - A Novel Splice Site Mutation in the 5'UTR of GATA1 resulting in Abnormal Hematopoiesis
Nam, J.
Namgyal, C.
Nanami, G.
Nandurkar, H.
4206 - High GRP78 (78-kDa Glucose-Regulated Protein) Expression Predicts for a Favorable Clinical Outcome in Patients with Multiple Myeloma and May be a Potentially Useful Therapeutic Target in the Treatment of Multiple Myeloma
4468 - Ten Years of Cerebral Venous Thrombosis (CVT) in Melbourne, Australia: Male Gender and Presence of Myeloproliferative Neoplasm Is Associated with Thrombotic Recurrence in Unprovoked Events
4468 - Ten Years of Cerebral Venous Thrombosis (CVT) in Melbourne, Australia: Male Gender and Presence of Myeloproliferative Neoplasm Is Associated with Thrombotic Recurrence in Unprovoked Events
Nanjappa, P.
1218 - XRCC5 Plays an Important Role in Homologous Recombination, Genome Stability and Survival of Myeloma Cells
1431 - Apurinic/Apyrimidinic Endonuclease 1 Induced Genomic Instability Causes T-Cell Acute Lymphoblastic Leukemia in Zebrafish
2420 - Nuclease Activity Is Associated with Genomic Instability As Well As Survival in Myeloma; Underlying Mechanisms and Significance
3625 - Critical Role of Split Hand/Foot Malformation Type 1 (SHFM1) in Homologous Recombination and Cell Survival in Multiple Myeloma (MM)
3626 - Functional and Genomic Signatures of Homologous Recombination (HR) Predict for Clinical Outcome in Multiple Myeloma (MM)
1431 - Apurinic/Apyrimidinic Endonuclease 1 Induced Genomic Instability Causes T-Cell Acute Lymphoblastic Leukemia in Zebrafish
2420 - Nuclease Activity Is Associated with Genomic Instability As Well As Survival in Myeloma; Underlying Mechanisms and Significance
3625 - Critical Role of Split Hand/Foot Malformation Type 1 (SHFM1) in Homologous Recombination and Cell Survival in Multiple Myeloma (MM)
3626 - Functional and Genomic Signatures of Homologous Recombination (HR) Predict for Clinical Outcome in Multiple Myeloma (MM)
Nanni, M.
2788 - Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience
2946 - Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study
2946 - Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study
Nanni, P.
Nannya, Y.
1515 - The Incidence and the Risk Factors of Bowel Perforation Due to Chemotherapy in Gastrointestinal Diffuse Large B Cell Lymphoma
2024 - Prognostic Impact of Cytogenetic Abnormalities in Adult Patients with Philadelphia-Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL) Who Underwent Allogeneic Stem Cell Transplant (allo-SCT)
2024 - Prognostic Impact of Cytogenetic Abnormalities in Adult Patients with Philadelphia-Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL) Who Underwent Allogeneic Stem Cell Transplant (allo-SCT)
Nantel, S. H.
Naoe, T.
79 - Effectiveness of High-Dose MTX Therapy for Adult Ph-Negative ALL By Randomized Trial: JALSG ALL202-O
1263 - Biomarker and Gene Profiling Analyses in Acute Myeloid Leukemia during Treatment with Hedgehog Signaling Inhibitor
1320 - ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study
1331 - A Photosensitizer Verteporfin Has Light-Independent Anti-Leukemic Activity for Ph-Positive Acute Lymphoblastic Leukemia and Synergistically Works with Dasatinib in Vivo
1353 - Development of FF-10101, a Novel Irreversible FLT3 Inhibitor, Which Overcomes Drug Resistance Mutations
2843 - Genetic Predispositions to Myeloid Neoplasms Caused By Germline DDX41 Mutations
2868 - A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)
3424 - Generation of BCR-ABL Reactive CD4+ T Helper Cells By Reprograming and Redifferentiation
4035 - Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study
1263 - Biomarker and Gene Profiling Analyses in Acute Myeloid Leukemia during Treatment with Hedgehog Signaling Inhibitor
1320 - ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study
1331 - A Photosensitizer Verteporfin Has Light-Independent Anti-Leukemic Activity for Ph-Positive Acute Lymphoblastic Leukemia and Synergistically Works with Dasatinib in Vivo
1353 - Development of FF-10101, a Novel Irreversible FLT3 Inhibitor, Which Overcomes Drug Resistance Mutations
2843 - Genetic Predispositions to Myeloid Neoplasms Caused By Germline DDX41 Mutations
2868 - A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)
3424 - Generation of BCR-ABL Reactive CD4+ T Helper Cells By Reprograming and Redifferentiation
4035 - Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study
Naparstek, E.
Napolitano, M.
Naqash, R.
Narang, M.
Narayan, R.
Narayanagari, S. R.
Narayanan, N.
Narayanan, S.
Narita, A.
Narita, A.
Narita, K.
Narita, K.
Narita, K.
Narkhede, M. S.
Narla, A.
Nascimento, M. M.
Naseem, S.
Naserullah, Z.
Nasir, S. S.
Nasirikenari, M.
Näsman-Glaser, B.
Naso, V.
Nasri, M.
Nassar, N.
Nasta, S. D.
Nastoupil, L.
255 - A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
470 - Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study
1502 - Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
1538 - Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results
2738 - The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma
2742 - A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma
3192 - In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials
3965 - The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies
3984 - The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL
3987 - High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial
470 - Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study
1502 - Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
1538 - Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results
2738 - The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma
2742 - A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma
3192 - In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials
3965 - The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies
3984 - The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL
3987 - High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial
Natarajan, K.
Nataren, N.
Nath, A.
Nath, C.
Nath, U.
Nathan, D. G.
Nathwani, B. N.
Nathwani, N.
Natkunam, Y.
Natoni, A.
1805 - E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271
3007 - Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma
3007 - Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma
Natour, M.
Natrajan, K.
Naumann, N.
Nava, T.
Navada, S. C.
Navada, S. C.
Navale, L.
2042 - Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy
2730 - Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
3991 - Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
4426 - Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy
2730 - Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
3991 - Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
4426 - Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy
Navarro, A.
Navarro, B.
Navarro, J. T.
Navarro, T.
Navarro-Bailón, A.
Navrkalova, V.
1712 - ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome
2918 - Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification
4126 - EGR2 Mutations in Chronic Lymphocytic Leukemia: A New Bad Player
2918 - Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification
4126 - EGR2 Mutations in Chronic Lymphocytic Leukemia: A New Bad Player
Nawa, Y.
Nawal, L.
Nawarawong, W.
1471 - Validation of German High-Grade Non-Hodgkin's Lymphoma (DSHNHL) Prognostic Model and the Impact of Treatment on Secondary Central Nervous System (CNS) Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) in a Developing Country: Report from the Nationwide Multi-Institutional Registry of Thai Lymphoma Study Group (TLSG)
2676 - Clinical Characteristics and Outcomes of Limited-Stage Primary Extranodal Versus Nodal Diffuse Large B-Cell Lymphoma (DLBCL) in Thailand: A Nationwide Multi-Institutional Registry of 920 Cases in Thailand
2712 - Consolidation Radiotherapy Improved Survival in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Nationwide Multi-Institutional Registry of 816 Cases in Thailand
3326 - Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand
2676 - Clinical Characteristics and Outcomes of Limited-Stage Primary Extranodal Versus Nodal Diffuse Large B-Cell Lymphoma (DLBCL) in Thailand: A Nationwide Multi-Institutional Registry of 920 Cases in Thailand
2712 - Consolidation Radiotherapy Improved Survival in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Nationwide Multi-Institutional Registry of 816 Cases in Thailand
3326 - Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand
Nawrocki, S. T.
1271 - Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy
1350 - Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML
1647 - Elevated Basal Autophagy in SF3B1 Mutated Myelodysplastic Syndromes: Relationship with Survival Outcomes and Therapeutic Implications
1807 - Small Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Refractory Multiple Myeloma
3022 - Antagonizing HDAC6 Activity: A New Strategy to Maximize the Anti-Myeloma Effects of BET Inhibition
1350 - Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML
1647 - Elevated Basal Autophagy in SF3B1 Mutated Myelodysplastic Syndromes: Relationship with Survival Outcomes and Therapeutic Implications
1807 - Small Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Refractory Multiple Myeloma
3022 - Antagonizing HDAC6 Activity: A New Strategy to Maximize the Anti-Myeloma Effects of BET Inhibition
Nayak, L. V.
Nayar, M.
Nayar, U.
Nayiager, T.
Nazha, A.
86 - The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML)
300 - Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia
439 - hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML
607 - The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS)
611 - Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes
907 - Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee
1259 - PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML
1271 - Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy
1319 - Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy
1645 - TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition
2216 - Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia
2888 - A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure
300 - Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia
439 - hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML
607 - The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS)
611 - Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes
907 - Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee
1259 - PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML
1271 - Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination Therapy
1319 - Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy
1645 - TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition
2216 - Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia
2888 - A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure
Nazi, I.
Nazimuddin, F.
683 - Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/ Refractory ALL
2523 - Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies
2523 - Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies
Ndonwi, M.
Ndour, P. A.
Neale, G. A.
Neale, M. C.
Neary, E.
Neben Wittich, M. A.
Nebor, D.
Neel, B.
Neelapu, S. S.
257 - Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma
1502 - Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
2051 - ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response
2730 - Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
2738 - The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma
2742 - A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma
3969 - Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial
3984 - The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL
3991 - Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
1502 - Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
2051 - ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response
2730 - Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
2738 - The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma
2742 - A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma
3969 - Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial
3984 - The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL
3991 - Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Neeson, P.
Neeves, K. B.
Neff, A. T.
Neff, T. L.
Neff, T.
Neggers, J. E.
Neglyad, L.
Negoro, E.
Negri, G.
Negrier, C.
2287 - Effect of Five Therapeutic Strategies on the Coagulation Defect Induced By the Thrombomodulin C.1611C>a Mutation
2298 - Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries
2298 - Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries
Négrier, C.
Negrin, R. S.
858 - Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients
1536 - Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis
1876 - Expanded CD4+Foxp3+ Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Disease after Allogeneic Transplantation
1885 - TNF-Alpha Priming Enhances CD4+FoxP3+ Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment
3232 - Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms
4284 - Increased Activity in the T Cell Effector Phase and Enhanced T Cell Repertoire Target-Tissue Stability Distinguish Alloreactivity Across Major Versus Minor Histocompatibility Barriers
- Graft-Versus-Host Disease vs. Graft-Versus-Leukemia Effect
1536 - Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis
1876 - Expanded CD4+Foxp3+ Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Disease after Allogeneic Transplantation
1885 - TNF-Alpha Priming Enhances CD4+FoxP3+ Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment
3232 - Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms
4284 - Increased Activity in the T Cell Effector Phase and Enhanced T Cell Repertoire Target-Tissue Stability Distinguish Alloreactivity Across Major Versus Minor Histocompatibility Barriers
- Graft-Versus-Host Disease vs. Graft-Versus-Leukemia Effect
Neilly, M. B.
3632 - Uncover TET1 Targets in MLL-Rearranged Leukemia
3667 - Overexpression and Knockout of Mir-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling
3784 - Targeted Treatment of FLT3-Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides
3667 - Overexpression and Knockout of Mir-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling
3784 - Targeted Treatment of FLT3-Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides
Neistadt, B.
Nejadnik, B.
737 - Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial
3121 - Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Results from an Ongoing Expanded Access Program
3273 - A Model Estimating Indirect Costs of Premature Death Associated with Severe Hepatic Veno-Occlusive Disease (sVOD) Among Hematopoietic Stem Cell Transplant (HSCT) Patients in the United States (U.S.)
3280 - Incidence of Hepatic Veno-Occlusive Disease (VOD) in Premier Healthcare Database
4311 - Early Initiation of Defibrotide in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation Improves Day +100 Survival
4330 - Pooled Treatment Analysis of Pediatric Patients with Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Multi-Organ Dysfunction Following Hematopoietic Stem Cell Transplant
4452 - Hospital Cost Associated with Veno-Occlusive Disease (VOD) in Patients with Hematopoietic Stem Cell Transplant (HSCT)
3121 - Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Results from an Ongoing Expanded Access Program
3273 - A Model Estimating Indirect Costs of Premature Death Associated with Severe Hepatic Veno-Occlusive Disease (sVOD) Among Hematopoietic Stem Cell Transplant (HSCT) Patients in the United States (U.S.)
3280 - Incidence of Hepatic Veno-Occlusive Disease (VOD) in Premier Healthcare Database
4311 - Early Initiation of Defibrotide in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation Improves Day +100 Survival
4330 - Pooled Treatment Analysis of Pediatric Patients with Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Multi-Organ Dysfunction Following Hematopoietic Stem Cell Transplant
4452 - Hospital Cost Associated with Veno-Occlusive Disease (VOD) in Patients with Hematopoietic Stem Cell Transplant (HSCT)
Nekhai, S. A.
936 - Thrombotic Complications Are Associated with Phlebotomy Therapy in Patients with Chuvash Polycythemia
3359 - Heme Oxygenase-1, Ferroportin and SAMHD1 Induction By Heme Inhibits HIV-1
3380 - Hydroxyurea Treatment Is Associated with Elevated Serum Erythropoietin Concentration but Suppressed Global Hypoxic Transcriptional Responses in Sickle Cell Disease
3418 - Semi-Automatic Enrichment with High Resolution/Selected Reaction Monitoring (HR/SRM) Scan for the Detection of Urinary Hepcidin in Patients with Sickle Cell Disease
3359 - Heme Oxygenase-1, Ferroportin and SAMHD1 Induction By Heme Inhibits HIV-1
3380 - Hydroxyurea Treatment Is Associated with Elevated Serum Erythropoietin Concentration but Suppressed Global Hypoxic Transcriptional Responses in Sickle Cell Disease
3418 - Semi-Automatic Enrichment with High Resolution/Selected Reaction Monitoring (HR/SRM) Scan for the Detection of Urinary Hepcidin in Patients with Sickle Cell Disease
Nekkar, P.
Nelakuditi, V.
Nelde, A.
Nelemans, P. J.
Nelin, L.
Nelson, J.
Nelson, K. A.
Nelson, K.
Nelson, L.
Nelson, S. C.
3 - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia
971 - Recognition of Biomarkers of Brain Connectivity and Pain Using Multi-Modal Imaging in Patients with Sickle Cell Disease
3393 - Genetic Modifiers Influencing the Development of Albuminuria in Children with Sickle Cell Anemia
971 - Recognition of Biomarkers of Brain Connectivity and Pain Using Multi-Modal Imaging in Patients with Sickle Cell Disease
3393 - Genetic Modifiers Influencing the Development of Albuminuria in Children with Sickle Cell Anemia
Nelson, W.
Nemet, D.
926 - Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission : Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT
3034 - Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice
3034 - Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice
Nemeth, E.
Nemeth, M. J.
Nemkov, T.
Nemoto-Anan, T.
Nemunaitis, J.
Nencioni, A.
Neo, W. H.
Neparidze, N.
Neppalli, V. T.
Neri, A.
616 - Microenvironment Regulation of IL23R/IL-23 Axis Drives Chronic Lymphocytic Leukemia (CLL) Progression
1729 - Differentially Expressed Protein Patterns in Chronic Lymphocytic Leukemia (CLL) after Thymosin beta4 (Tb4) and Lenalidomide (Len) Treatment: Two-Dimensional Gel Electrophoresis (2DE) Analysis
2930 - A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients
2946 - Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study
3019 - Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines
3025 - Pharmacokinetics and Biodistribution of Locked Nucleic Acid (LNA)-Mir-221 Inhibitor: A New Promising Anti-Myeloma Agent
1729 - Differentially Expressed Protein Patterns in Chronic Lymphocytic Leukemia (CLL) after Thymosin beta4 (Tb4) and Lenalidomide (Len) Treatment: Two-Dimensional Gel Electrophoresis (2DE) Analysis
2930 - A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients
2946 - Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study
3019 - Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines
3025 - Pharmacokinetics and Biodistribution of Locked Nucleic Acid (LNA)-Mir-221 Inhibitor: A New Promising Anti-Myeloma Agent
Neri, M. G.
956 - Association Between Serum Ferritin and Liver Iron Concentration with Cardiac Iron in Pediatric Thalassemia Major Patients
2077 - A Cost-Utility Analysis of Deferiprone Compared to Desferrioxamine and Deferasirox for the Treatment of Chronic Myocardial Iron Overload in Thalassemia Patients
2154 - Prevalence of Extramedullary Hematopoiesis, Vertebral, Hepatic and Splenic Hemangioma and Renal Cyst Among Thalassaemic Patients: A Retrospective Study from the Myocardial Iron in Thalassemia (MIOT) Network
2159 - Deferiprone Has a Dose-Dependent Effect on Liver Iron Concentration
3367 - Changes of Cardiac Iron and Function during Pregnancy in Trasfusion-Dependent Thalassemia Patients
2077 - A Cost-Utility Analysis of Deferiprone Compared to Desferrioxamine and Deferasirox for the Treatment of Chronic Myocardial Iron Overload in Thalassemia Patients
2154 - Prevalence of Extramedullary Hematopoiesis, Vertebral, Hepatic and Splenic Hemangioma and Renal Cyst Among Thalassaemic Patients: A Retrospective Study from the Myocardial Iron in Thalassemia (MIOT) Network
2159 - Deferiprone Has a Dose-Dependent Effect on Liver Iron Concentration
3367 - Changes of Cardiac Iron and Function during Pregnancy in Trasfusion-Dependent Thalassemia Patients
Neri, P.
1789 - Resistance to Lenalidomide in Multiple Myeloma Is Associated with a Switch in Gene Expression Profile
1845 - Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma
1846 - Bortezomib-Containing Regimens (BCR) for the Treatment of Non-Transplant Eligible Multiple Myeloma
3189 - Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center
4175 - Ikaros-Dependent Downregulation of MYC with IMiDs in Myeloma (MM) Cells Is Mediated through the Depletion of the Acetylated Chromatin Reader BRD4 at Super-Enhancer Loci
4261 - In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort
1845 - Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma
1846 - Bortezomib-Containing Regimens (BCR) for the Treatment of Non-Transplant Eligible Multiple Myeloma
3189 - Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center
4175 - Ikaros-Dependent Downregulation of MYC with IMiDs in Myeloma (MM) Cells Is Mediated through the Depletion of the Acetylated Chromatin Reader BRD4 at Super-Enhancer Loci
4261 - In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort
Nerl, C.
Nerlov, C.
Nesbitt, N.
Ness, K. K.
739 - Physiologic Frailty Among Hematopoietic Cell Transplantation (HCT) Survivors Suggests Accelerated Aging and Is a Predictor for Premature Mortality: A Report from the Bone Marrow Transplant Survivor Study (BMTSS)
4480 - Neurocognitive, Psychosocial, and Quality of Life Outcomes in Adult Survivors of Childhood Non-Hodgkin Lymphoma in the St. Jude Lifetime (SJLIFE) Cohort
4480 - Neurocognitive, Psychosocial, and Quality of Life Outcomes in Adult Survivors of Childhood Non-Hodgkin Lymphoma in the St. Jude Lifetime (SJLIFE) Cohort
Ness, P. M.
Nesvizhskii, A. I.
Neubauer, A.
599 - Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial
858 - Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients
1309 - Adverse Prognosis in Acute Myeloid Leukemia with Abnormality Abn(3q): Does EVI1 Matter?
858 - Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients
1309 - Adverse Prognosis in Acute Myeloid Leukemia with Abnormality Abn(3q): Does EVI1 Matter?
Neuberg, D. S.
80 - A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial
176 - PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
248 - Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001
249 - Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia
251 - Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001
306 - Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia
362 - Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy
366 - Expression of Sf3b1-K700E in Murine B Cells Causes Pre-mRNA Splicing and Altered B Cell Differentiation and Function
543 - Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE)
631 - The Impact of Insurance Status at Diagnosis on Overall Survival in Chronic Myeloid Leukemia: A Population-Based Analysis
907 - Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee
1304 - Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center
1713 - High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia
2549 - DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions
2597 - Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia
2613 - Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease
2655 - Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets
2672 - The Impact of Age and Sex in DLBCL: Determination of Biologic Dynamics and Delineation of Inter-Connected Signaling Networks Via a Systems Biology Analysis
2906 - Comprehensive Bulk and Single Cell Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia
3318 - The End of Life for Patients with Acute Myeloid Leukemia (AML)- a Single Center Experience
3753 - Comparison of Age at Diagnosis, Cytogenetic Risk, and Overall Survival Between Acute Myeloid Leukemia Patients of White and South Asian Race/Ethnicity in the United States
3765 - Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia
3922 - Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma
176 - PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
248 - Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001
249 - Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia
251 - Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001
306 - Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia
362 - Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy
366 - Expression of Sf3b1-K700E in Murine B Cells Causes Pre-mRNA Splicing and Altered B Cell Differentiation and Function
543 - Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE)
631 - The Impact of Insurance Status at Diagnosis on Overall Survival in Chronic Myeloid Leukemia: A Population-Based Analysis
907 - Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee
1304 - Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center
1713 - High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia
2549 - DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions
2597 - Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia
2613 - Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease
2655 - Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets
2672 - The Impact of Age and Sex in DLBCL: Determination of Biologic Dynamics and Delineation of Inter-Connected Signaling Networks Via a Systems Biology Analysis
2906 - Comprehensive Bulk and Single Cell Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia
3318 - The End of Life for Patients with Acute Myeloid Leukemia (AML)- a Single Center Experience
3753 - Comparison of Age at Diagnosis, Cytogenetic Risk, and Overall Survival Between Acute Myeloid Leukemia Patients of White and South Asian Race/Ethnicity in the United States
3765 - Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia
3922 - Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma
Neubert, T. A.
Neuenburg, J.
470 - Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study
1527 - Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL
3998 - Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP
1527 - Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL
3998 - Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP
Neufeld, E. J.
Neukirchen, J.
Neumann, A. L.
Neumann, D.
Neumann, F.
1817 - Peripheral B Cells from Patients with MGUS and Multiple Myeloma (MM) Can Be Stimulated by Paraprotein-Target Specific T-Helper Cells to Produce Paraprotein-Identical Monoclonal Antibodies: Rationale for PARs, a Novel Therapeutic Approach with Ultimate Specificity in MGUS/MM
2203 - Lenalidomide Enhances MOR202 Dependent Macrophage-Mediated Effector Functions Via the Vitamin D Pathway
2734 - Optimizing 25-OH-Vitamin D3 Serum Levels for Rituximab- and Obinutuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity
3995 - BARs (B-cell receptor antigens for reverse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms
2203 - Lenalidomide Enhances MOR202 Dependent Macrophage-Mediated Effector Functions Via the Vitamin D Pathway
2734 - Optimizing 25-OH-Vitamin D3 Serum Levels for Rituximab- and Obinutuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity
3995 - BARs (B-cell receptor antigens for reverse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms
Neumann, M.
690 - Mutations of Genes Linked to Epigenetic Regulation Are Frequently Gained in Relapsed Cytogenetically Normal Acute Myeloid Leukemia
804 - Acute Myeloid Leukemia in the Elderly Is Characterized By a Distinct Genetic Landscape
2625 - Genomic Profiling Reveals Gain of Mutations in Histone Methylation Regulators in Relapsed Adult B Cell Precursor ALL
2859 - Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)
3843 - Molecular Alterations in Refractory Acute Myeloid Leukemia and Persistent Preleukemic Lesions Are Disclosed Using Mesenchymal Stromal Cells As Germline Control
3859 - Detection of Chromosomal Aberrations in Acute Myeloid Leukemia By Copy Number Alteration Analysis of Exome Sequencing Data
804 - Acute Myeloid Leukemia in the Elderly Is Characterized By a Distinct Genetic Landscape
2625 - Genomic Profiling Reveals Gain of Mutations in Histone Methylation Regulators in Relapsed Adult B Cell Precursor ALL
2859 - Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)
3843 - Molecular Alterations in Refractory Acute Myeloid Leukemia and Persistent Preleukemic Lesions Are Disclosed Using Mesenchymal Stromal Cells As Germline Control
3859 - Detection of Chromosomal Aberrations in Acute Myeloid Leukemia By Copy Number Alteration Analysis of Exome Sequencing Data
Neumayr, L.
Neumeister, P.
2444 - Loss of NR4A1 Accelerates the Development of Aggressive Lymphomas in Myc Induced Cancerogenesis
2674 - NR4A3 Possesses Tumor Suppressive Properties like NR4A1 By Regulating Pro-Apoptotic Genes in Aggressive Lymphomas and Serves As a Potential Drug Target for Lymphoma Therapy
3890 - The Chemokine Receptor Profile As Distinctive Criterion Between Normal B-Cell Subsets and As Potential Discriminative Marker to Identify the Cell of Origin in Patients with Chronic Lymphocytic Leukemia and Richter Syndrome
3973 - AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)
2674 - NR4A3 Possesses Tumor Suppressive Properties like NR4A1 By Regulating Pro-Apoptotic Genes in Aggressive Lymphomas and Serves As a Potential Drug Target for Lymphoma Therapy
3890 - The Chemokine Receptor Profile As Distinctive Criterion Between Normal B-Cell Subsets and As Potential Discriminative Marker to Identify the Cell of Origin in Patients with Chronic Lymphocytic Leukemia and Richter Syndrome
3973 - AGMT MALT-2: A Phase II Study of Rituximab Plus Lenalidomide in Patients with Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma)
Neunert, C.
Neuwelt, A.
Neven, B.
202 - Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector
544 - French National Drepagreffe Trial: Cognitive Performances and Neuroimaging at Enrollment and after 12 Months on Transfusion Program or Transplantation (AP-HP: NCT 01340404)
544 - French National Drepagreffe Trial: Cognitive Performances and Neuroimaging at Enrollment and after 12 Months on Transfusion Program or Transplantation (AP-HP: NCT 01340404)
Neven, B.
541 - Hematopoietic Stem Cell Transplantation from HLA Identical Sibling Forsickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR
3235 - B Cell Reconstitution after Gene Therapy in Patients with Wiskott Aldrich Syndrome and Comparison with Mismatched Allogeneic Hematopoietic Stem Cell Transplantation
4326 - Reiterated Therapeutic Drug Monitoring (TDM) Dosing to Significantly Improve the Control of Exposure to IV Busulfan in Infants and Older Children Undergoing Hematopoietic Stem-Cell Transplantation (HSCT)
3235 - B Cell Reconstitution after Gene Therapy in Patients with Wiskott Aldrich Syndrome and Comparison with Mismatched Allogeneic Hematopoietic Stem Cell Transplantation
4326 - Reiterated Therapeutic Drug Monitoring (TDM) Dosing to Significantly Improve the Control of Exposure to IV Busulfan in Infants and Older Children Undergoing Hematopoietic Stem-Cell Transplantation (HSCT)
Neves, M.
Nevill, T. J.
1701 - Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study
3770 - Pediatric-Based Versus Adult Treatment Protocols in Young Adults (18-40 years) with Standard Risk Acute Lymphoblastic Leukemia: The BC Cancer Agency Experience
3770 - Pediatric-Based Versus Adult Treatment Protocols in Young Adults (18-40 years) with Standard Risk Acute Lymphoblastic Leukemia: The BC Cancer Agency Experience
New, H.
1906 - Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in Haemoglobinopathies Leads to Early and Sustanined Engraftment with Low Incidence of VOD and GvHD
4317 - Haploidentical BMT with a Post-Infusion of Stem Cells Cyclophosphamide Approach Is Feasible and Leads to a High Rate of Donor Engraftment in Haemoglobinopathies Allowing Universal Application of Transplantation
4317 - Haploidentical BMT with a Post-Infusion of Stem Cells Cyclophosphamide Approach Is Feasible and Leads to a High Rate of Donor Engraftment in Haemoglobinopathies Allowing Universal Application of Transplantation
New, J. Y.
Newberry, K. J.
Newburger, P. E.
996 - Long Term Outcomes for Patients with Cyclic Neutropenia Treated with Granulocyte Colony-Stimulating Factor (G-CSF)
2136 - The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status
2211 - Is There a Role for Anti-Neutrophil Antibody Testing in Predicting Spontaneous Resolution of Neutropenia in Young Children
3337 - Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants
2136 - The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status
2211 - Is There a Role for Anti-Neutrophil Antibody Testing in Predicting Spontaneous Resolution of Neutropenia in Young Children
3337 - Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants
Newbury-Ecob, R.
Newcomb, T.
Newell, L. F.
Newkold, T. J.
Newman, A. M.
Newman, E. M.
2731 - Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies
3977 - Efficacy and Safety of Combined Rituximab and Ipilimumab to Treat Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma
3977 - Efficacy and Safety of Combined Rituximab and Ipilimumab to Treat Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma
Newman, E.
Newman, P. J.
1041 - Structural Basis for PECAM-1 Homophilic Binding
1107 - Quantitative Measurement of VWF Binding to the Platelet Integrin αIIbβ3 – Abnormalities Identified in Individuals with VWD
2340 - Involvement of the EGF Domain in the Formation of the Human Platelet Alloantigen, HPA-1a
2341 - Crispr/Cas9-Mediated Generation of Mouse Platelets Expressing the Human Platelet Alloantigen, HPA-1a
3450 - Species-Specific Roles for a2,3- and a2,6-Linked Sialic Acid Residues in PECAM-1-Mediated Homophilic Interactions
1107 - Quantitative Measurement of VWF Binding to the Platelet Integrin αIIbβ3 – Abnormalities Identified in Individuals with VWD
2340 - Involvement of the EGF Domain in the Formation of the Human Platelet Alloantigen, HPA-1a
2341 - Crispr/Cas9-Mediated Generation of Mouse Platelets Expressing the Human Platelet Alloantigen, HPA-1a
3450 - Species-Specific Roles for a2,3- and a2,6-Linked Sialic Acid Residues in PECAM-1-Mediated Homophilic Interactions
Newmarch, M.
Neylon, E.
586 - The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience
1280 - Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma
1282 - Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development
1280 - Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma
1282 - Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development
Ng, A.
Ng, C.
Ng, C. H.
Ng, K. P.
Ng, P. C.
995 - Gene Expressional Profile of Neonatal Neutrophils in Response to Bacterial Lipopolysaccharide (LPS) and Possible Mechanism of Transcription Factor NR4A2 on the Immune Signal Cascade
1169 - The Tetraspanin CD9 Regulates Engraftment and Mobilization of Human CD34+ Hematopoietic Stem/Progenitor Cells and Modulates VLA-4 Activity
2371 - RGS1 and RGS13 Regulate SDF-1-Mediated Responses and Homing in Human Cord Blood CD34+ Hematopoietic Stem/Progenitor Cells
1169 - The Tetraspanin CD9 Regulates Engraftment and Mobilization of Human CD34+ Hematopoietic Stem/Progenitor Cells and Modulates VLA-4 Activity
2371 - RGS1 and RGS13 Regulate SDF-1-Mediated Responses and Homing in Human Cord Blood CD34+ Hematopoietic Stem/Progenitor Cells
Ng, P. P.
Ng, P.
Ng, S.
Ng, S. W.
Ngankeu, A.
Ngoc-Tung, T.
Nguyen, B.
Nguyen, B.
Nguyen, H.
1873 - CD8 Tregs Promote Gvhd Prevention and Restore Impaired GVL Effect Mediated By CD4 Tregs in Mice
1874 - Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation
3074 - PIM2 Kinase Regulates T-Cell Alloresponses and Graft-Versus-Host Disease in Mice
3076 - Targeting Host Complement C3a/C5a Receptors to Control of Acute Graft-Versus-Host Disease in Mice
1874 - Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation
3074 - PIM2 Kinase Regulates T-Cell Alloresponses and Graft-Versus-Host Disease in Mice
3076 - Targeting Host Complement C3a/C5a Receptors to Control of Acute Graft-Versus-Host Disease in Mice
Nguyen, J. M.
Nguyen, J. V.
Nguyen, J.
412 - Hemopexin Gene Therapy Inhibits Inflammation and Vaso-Occlusion in Transgenic Sickle Cell Mice
2163 - Three Months of Human Haptoglobin Treatment Decreases Iron Deposition in the Kidneys of Townes Sickle Mice
3385 - Hemin-Induced Mast Cell-Extracellular Traps Impart Resistance to Therapy in a Sickle Microenvironment
2163 - Three Months of Human Haptoglobin Treatment Decreases Iron Deposition in the Kidneys of Townes Sickle Mice
3385 - Hemin-Induced Mast Cell-Extracellular Traps Impart Resistance to Therapy in a Sickle Microenvironment
Nguyen, K.
Nguyen, M. H.
Nguyen, N.
Nguyen, P.
Nguyen, P. L.
Nguyen Quoc, S.
Nguyen quoc, S.
1946 - Skin Immune Stimulation By Infections and Drug Toxicities during Induction and/or Consolidations Increases Incidence of Skin Acute Graft Versus Host Disease in Acute Myeloid Leukemia: A Study on Behalf of SFGM-TC and ALFA
3222 - RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Intermediate Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO & SFGM-TC French intergroup)
4367 - Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)
3222 - RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Intermediate Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO & SFGM-TC French intergroup)
4367 - Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)
Nguyen, S. M.
1432 - CRLF2/Tslpr Overexpressing Acute Lymphoblastic Leukemia Relapse Is Driven By Chemotherapy-Induced TSLP from Bone Marrow Stromal Cells
2524 - Lineage Switch As a Relapse Mechanism of Pre-B Acute Lymphoblastic Leukemia Following CD19 CAR
4427 - Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22
2524 - Lineage Switch As a Relapse Mechanism of Pre-B Acute Lymphoblastic Leukemia Following CD19 CAR
4427 - Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22
Nguyen, S.
1922 - Impact of Early Post-Transplant Complications on Survival of Patients with Myelodysplastic Syndrome Undergoing Allo-SCT Following Reduced Intensity Conditioning: An SFGM-TC Study
3208 - Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)
3208 - Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)
Nguyen, T. K.
Nguyen, T.
Nguyen, T.
Nguyen, V. T.
Nguyen, V.
Nguyen-Khac, F.
Nguyen-Quoc, S.
Nguyen-Thi, P. L.
Ní Áinle, F.
Ni, H.
12 - Platelet GPIba Is Important for Thrombopoietin Production and Thrombopoietin-Induced Platelet Generation
1045 - Successful Treatment of Thrombocytopenia with Staphylococcal Protein A (PRTX-100) in a Murine Model of Immune Thrombocytopenia (ITP)
1048 - Effects of Anti-Glycoprotein Antibodies on Response of Immune Thrombocytopenia Patients to Thrombopoietin Receptor Agonists and on Megakaryocytes Viability
2251 - Thymic-Derived Tolerizing Dendritic Cells Are up-Regulated upon Treatment with Intravenous Immunoglobulin or Splenectomy in a Murine Model of Immune Thrombocytopenia
2254 - Natural Killer Cells Contribute to Pathophysiology of Placenta Leading to Miscarriage in Fetal and Neonatal Alloimmune Thrombocytopenia
1045 - Successful Treatment of Thrombocytopenia with Staphylococcal Protein A (PRTX-100) in a Murine Model of Immune Thrombocytopenia (ITP)
1048 - Effects of Anti-Glycoprotein Antibodies on Response of Immune Thrombocytopenia Patients to Thrombopoietin Receptor Agonists and on Megakaryocytes Viability
2251 - Thymic-Derived Tolerizing Dendritic Cells Are up-Regulated upon Treatment with Intravenous Immunoglobulin or Splenectomy in a Murine Model of Immune Thrombocytopenia
2254 - Natural Killer Cells Contribute to Pathophysiology of Placenta Leading to Miscarriage in Fetal and Neonatal Alloimmune Thrombocytopenia
Ni, X.
3981 - Blood Transcriptional Profiling in Patients with Leukemic Cutaneous T-Cell Lymphoma on Extracorporeal Photopheresis Reveals the Integrin Signaling As the Top Pathway Associated with Clinical Response
4011 - ONC201 Induces Apoptosis in Cutaneous T-Cell Lymphoma Cells through a Mechanism That Involves the Integrated Stress Response and Inactivation of Jak/Stat Signaling
4011 - ONC201 Induces Apoptosis in Cutaneous T-Cell Lymphoma Cells through a Mechanism That Involves the Integrated Stress Response and Inactivation of Jak/Stat Signaling
Ni, X.
Niazi, S.
Nibourel, O.
Nibumona, S.
Nichelatti, M.
2248 - Is Ashwell-Morell Receptor Mediated Hepatic Clearance of Platelet Clinically Relevant in Immune Thrombocytopenia (ITP)? a Retrospective Analysis of Platelet Kinetic Studies and Autoantibody Type Data
3462 - Thrombopoietin Receptor Agonist (TPO-RA) Switch in Adult Primary Immune Thrombocytopenia (ITP) Patients: A Retrospective Collaborative Survey from 8 Italian Hematology Centers
3462 - Thrombopoietin Receptor Agonist (TPO-RA) Switch in Adult Primary Immune Thrombocytopenia (ITP) Patients: A Retrospective Collaborative Survey from 8 Italian Hematology Centers
Nichele, I.
Nichol, G.
Nicholas, N. S.
Nicholas, S.
Nichols, G.
Nichols, G.
673 - BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms
2580 - Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells
2580 - Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells
Nichols, J.
Nichols, K. E.
Nichols, T. C.
Nichols, Jr., W. L.
Nicholson, L.
Nicholson, R. T.
Nickel, R. S.
Nickels, E.
Nickelsen, M.
Nickolay*, L.
Nicolas-Virelizier, E.
Nicolas-Virelizier, E.
577 - Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study
1544 - Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution
1544 - Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution
Nicolau-Travers, M. L.
Nicole, C. M.
Nicolini, F. E.
134 - Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)
137 - Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort
345 - Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients
480 - The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation
1317 - Acute Myeloid Leukemia in Elderly Patients: Experience of the Antoine Lacassagne Center and a New Score to Define Fit Patients
1578 - Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results
2577 - Mixed Chimerism at Three Months after Allogeneic Hematopoietic Stem Cell Transplantation Is a Significant Predictor of Disease Relapse in High-Risk Acute Myeloid Leukemia Patients in First Complete Remission
2774 - Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients
2790 - A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients
2817 - EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 109/L to 99 × 109/L) at Baseline
3213 - Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Peripheral Blood or Bone Marrow Donors: The Impact of HLA Matching Including HLA-DPB1 Allele in a Multivariable Risk Model
3428 - Survey of Serum Aspergillus Antigen in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia or Allogeneic Hematopoietic Stem Cell Transplantation: Role in Predicting Invasive Aspergillosis and in Modifying the Therapeutic Strategy
4025 - Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial
4039 - Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study
4324 - Optimizing the Outcomes of Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Hematological Malignancies: The Perfect Combination of Conditioning Regimen, Disease Stage and Type of HSC Donor
4477 - First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
137 - Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort
345 - Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients
480 - The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation
1317 - Acute Myeloid Leukemia in Elderly Patients: Experience of the Antoine Lacassagne Center and a New Score to Define Fit Patients
1578 - Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results
2577 - Mixed Chimerism at Three Months after Allogeneic Hematopoietic Stem Cell Transplantation Is a Significant Predictor of Disease Relapse in High-Risk Acute Myeloid Leukemia Patients in First Complete Remission
2774 - Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients
2790 - A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients
2817 - EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 109/L to 99 × 109/L) at Baseline
3213 - Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Peripheral Blood or Bone Marrow Donors: The Impact of HLA Matching Including HLA-DPB1 Allele in a Multivariable Risk Model
3428 - Survey of Serum Aspergillus Antigen in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia or Allogeneic Hematopoietic Stem Cell Transplantation: Role in Predicting Invasive Aspergillosis and in Modifying the Therapeutic Strategy
4025 - Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial
4039 - Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study
4324 - Optimizing the Outcomes of Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Hematological Malignancies: The Perfect Combination of Conditioning Regimen, Disease Stage and Type of HSC Donor
4477 - First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Nicolosi, M.
Niculescu, L.
Nie, K.
7 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)
3467 - Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)
3467 - Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)
Nieborowska-Skorska, M.
Niederwieser, D.
1346 - Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)
2014 - The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis
2438 - Next Generation Sequencing and Functional Analysis of Mirna Expression in Acute Myeloid Leukemia Patients with Different FLT3 Mutations: Block of MiR-155 in FLT3-ITD Driven AML Leads to Downregulation of Myeloid Blasts in Vivo
4492 - Hematopoietic Stem Cell Transplant Activity in Latin America: Predominant Increase in Autologous and Modest Increase in Allogeneic HCT with High Use of Unrelated Cord Blood Grafts
2014 - The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis
2438 - Next Generation Sequencing and Functional Analysis of Mirna Expression in Acute Myeloid Leukemia Patients with Different FLT3 Mutations: Block of MiR-155 in FLT3-ITD Driven AML Leads to Downregulation of Myeloid Blasts in Vivo
4492 - Hematopoietic Stem Cell Transplant Activity in Latin America: Predominant Increase in Autologous and Modest Increase in Allogeneic HCT with High Use of Unrelated Cord Blood Grafts
Niederwieser, D.
6 - The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])
63 - Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT
135 - Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial
480 - The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation
1958 - Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT
2032 - High Expression of the Hedgehog Transcription Factor GLI1 Is Associated with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Non-Myeloablative Conditioning
2517 - Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies
2573 - Unsupervised Cluster Analysis of Antigen Expression Patterns Identifies Subgroups with Distinct Biological and Clinical Features in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
3223 - The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes
3829 - Prognostic Impact of Aberrant RUNX1 Expression in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4040 - Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase
4390 - Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT
4398 - Assessment of NPM1 Type a Mutation Burden By Digital Droplet PCR As a Marker of Minimal Residual Disease in Acute Myeloid Leukemia Patients Undergoing Stem Cell Transplantation
63 - Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT
135 - Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial
480 - The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation
1958 - Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT
2032 - High Expression of the Hedgehog Transcription Factor GLI1 Is Associated with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Non-Myeloablative Conditioning
2517 - Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies
2573 - Unsupervised Cluster Analysis of Antigen Expression Patterns Identifies Subgroups with Distinct Biological and Clinical Features in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
3223 - The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes
3829 - Prognostic Impact of Aberrant RUNX1 Expression in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4040 - Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase
4390 - Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT
4398 - Assessment of NPM1 Type a Mutation Burden By Digital Droplet PCR As a Marker of Minimal Residual Disease in Acute Myeloid Leukemia Patients Undergoing Stem Cell Transplantation
Nielsen, A.
Nielsen, K. F.
Nielsen, P.
Nielsen, S. R.
Nielsen Viller, N.
Nieman, M. T.
Niemann, C.
1740 - Improved Survival for Patients with CLL in the Era of Combination Chemoimmunotherapy - a Danish Population Based Study
2920 - The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia
2921 - Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?
2920 - The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia
2921 - Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?
Niemann, F. S.
Niemeyer, C. M.
299 - Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency
438 - Epigenetic Changes Accompany Disordered Hemoglobin Regulation in Juvenile Myelomonocytic Leukemia
1655 - 5-Azacytidine Reduces Leukemic Burden in a Xenograft Model of Juvenile Myelomonocytic Leukemia
1657 - The Integrated Immunological Signature of Refractory Cytopenia of Childhood (RCC)
1662 - Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes
2851 - Microrna-150 Regulates STAT5b Levels in Juvenile Myelomonocytic Leukemia (JMML)
SCI-12 - Clonal Mutations and Clonal Hierarchy in Pediatric Myeloid Neoplasms
438 - Epigenetic Changes Accompany Disordered Hemoglobin Regulation in Juvenile Myelomonocytic Leukemia
1655 - 5-Azacytidine Reduces Leukemic Burden in a Xenograft Model of Juvenile Myelomonocytic Leukemia
1657 - The Integrated Immunological Signature of Refractory Cytopenia of Childhood (RCC)
1662 - Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes
2851 - Microrna-150 Regulates STAT5b Levels in Juvenile Myelomonocytic Leukemia (JMML)
SCI-12 - Clonal Mutations and Clonal Hierarchy in Pediatric Myeloid Neoplasms
Niemeyer, G. P.
Niestadt, B.
Niesvizky, R.
30 - Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866)
377 - Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study
378 - Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)
500 - Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation
722 - Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study
729 - Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866)
731 - Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)
1844 - Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup
2991 - Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma
3040 - ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)
4232 - Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib
4250 - Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)
4258 - High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma
377 - Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study
378 - Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)
500 - Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation
722 - Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study
729 - Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866)
731 - Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)
1844 - Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup
2991 - Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma
3040 - ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)
4232 - Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib
4250 - Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)
4258 - High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma
Nieto, J. B.
Nieto, J. B.
Nieto, Y.
152 - Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation
187 - Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
396 - Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM)
738 - Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial
854 - A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids
929 - Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study
1979 - Autologous Hematopoietic Cell Transplantation in Patients with High Risk Multiple Myeloma: Post- Transplant Responses Do Not Translate to Longer Survival
1980 - Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM
1992 - Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma
2738 - The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma
3128 - Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft Vs. Host Disease
3136 - Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit
3155 - Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
3186 - Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients
3194 - Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant
3984 - The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL
4376 - Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results
187 - Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
396 - Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM)
738 - Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial
854 - A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids
929 - Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study
1979 - Autologous Hematopoietic Cell Transplantation in Patients with High Risk Multiple Myeloma: Post- Transplant Responses Do Not Translate to Longer Survival
1980 - Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM
1992 - Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma
2738 - The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma
3128 - Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft Vs. Host Disease
3136 - Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit
3155 - Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
3186 - Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients
3194 - Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant
3984 - The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL
4376 - Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results
Nietubicz, C.
Nievergall, E.
Niewerth, D.
2501 - Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics
3712 - Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells
3712 - Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells
Nii, T.
Niihara, Y.
Niitsu, N.
Niittyvuopio, R.
Niiya, D.
Nijhof, I.
Nijland, M.
Nikiforow, S.
742 - Venous Thromboembolism Is Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
857 - Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations
919 - IL-2 Induces Selective Activation of Helios-Positive Regulatory T Cells and CD56bright NK Cells in Vitro and in Patients with Chronic Gvhd Receiving Low-Dose IL-2 Therapy
3133 - Long-Term Homeostatic Effects of Daily Low-Dose IL-2 on CD4+ FoxP3+ Regulatory T Cells in Patients with Active Chronic Graft-Versus-Host Disease
857 - Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations
919 - IL-2 Induces Selective Activation of Helios-Positive Regulatory T Cells and CD56bright NK Cells in Vitro and in Patients with Chronic Gvhd Receiving Low-Dose IL-2 Therapy
3133 - Long-Term Homeostatic Effects of Daily Low-Dose IL-2 on CD4+ FoxP3+ Regulatory T Cells in Patients with Active Chronic Graft-Versus-Host Disease
Nikitin, E.
Nikitina, T.
1845 - Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma
4261 - In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort
4261 - In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort
Nikolinakos, P. G.
Nikolopoulos, S.
Nikonova, A.
Nimeiri, H. S.
Nimer, S. D.
303 - HIF-1a Pathway, As a Signal Funnel for Genetic, Epigenetic, and Metabolic Aberrations, Is Sufficient and Essential for MDS Development
714 - MSI2 Is Required for Maintaining the Activated Myelodysplastic Syndrome Stem Cell
1181 - Prmt5 Negatively Regulates Erythropoiesis By Multiple Mechanisms, Including Controlling DNA Methyltransferase 3A Protein Levels
1247 - Integrative Analysis of the Mutational Landscape of Mouse and Human AML Identifies Functionally Relevant Leukemia Disease Alleles
714 - MSI2 Is Required for Maintaining the Activated Myelodysplastic Syndrome Stem Cell
1181 - Prmt5 Negatively Regulates Erythropoiesis By Multiple Mechanisms, Including Controlling DNA Methyltransferase 3A Protein Levels
1247 - Integrative Analysis of the Mutational Landscape of Mouse and Human AML Identifies Functionally Relevant Leukemia Disease Alleles
Nimmagadda, R.
Ninet, J.
Ning, Y.
Ninivaggi, M.
Ninomiya, S.
Niparuck, P.
1471 - Validation of German High-Grade Non-Hodgkin's Lymphoma (DSHNHL) Prognostic Model and the Impact of Treatment on Secondary Central Nervous System (CNS) Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) in a Developing Country: Report from the Nationwide Multi-Institutional Registry of Thai Lymphoma Study Group (TLSG)
2676 - Clinical Characteristics and Outcomes of Limited-Stage Primary Extranodal Versus Nodal Diffuse Large B-Cell Lymphoma (DLBCL) in Thailand: A Nationwide Multi-Institutional Registry of 920 Cases in Thailand
2712 - Consolidation Radiotherapy Improved Survival in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Nationwide Multi-Institutional Registry of 816 Cases in Thailand
3326 - Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand
2676 - Clinical Characteristics and Outcomes of Limited-Stage Primary Extranodal Versus Nodal Diffuse Large B-Cell Lymphoma (DLBCL) in Thailand: A Nationwide Multi-Institutional Registry of 920 Cases in Thailand
2712 - Consolidation Radiotherapy Improved Survival in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Nationwide Multi-Institutional Registry of 816 Cases in Thailand
3326 - Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand
Nirenberg, D.
Niro, A.
Nirujogi, R. S.
Niscola, P.
91 - Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial
2099 - Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study
2120 - Quality of Life in Elderly Patients with Acute Myeloid Leukemia Undergoing Induction Chemotherapy
2099 - Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study
2120 - Quality of Life in Elderly Patients with Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Nishida, A.
Nishida, H.
Nishida, T.
97 - Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
1021 - PD-L1 on Antigen-Presenting Cells Facilitate the Induction of Antigen-Specific Cytotoxic T Lymphocytes
4424 - A Novel Strategy of Switching on/Off CD19CAR Expression Under Tetracycline-Based System
1021 - PD-L1 on Antigen-Presenting Cells Facilitate the Induction of Antigen-Specific Cytotoxic T Lymphocytes
4424 - A Novel Strategy of Switching on/Off CD19CAR Expression Under Tetracycline-Based System
Nishida, Y.
Nishiguchi, K.
Nishihori, T.
2097 - Myeloablative or Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Mantle Cell Lymphoma? a Systematic Review and Meta-Analysis
4382 - TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
4407 - Hypo-Albuminemia at Day+90 after Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies Independently Predicts for Inferior Overall Survival and Higher Non-Relapse Mortality
4382 - TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
4407 - Hypo-Albuminemia at Day+90 after Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies Independently Predicts for Inferior Overall Survival and Higher Non-Relapse Mortality
Nishii, R.
Nishikawa, H.
Nishikawa, S.
Nishikii, H.
1876 - Expanded CD4+Foxp3+ Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Disease after Allogeneic Transplantation
1885 - TNF-Alpha Priming Enhances CD4+FoxP3+ Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment
1885 - TNF-Alpha Priming Enhances CD4+FoxP3+ Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment
Nishimori, H.
Nishimoto, M.
Nishimura, J. I.
Nishimura, N.
Nishimura, N.
Nishimura, R.
Nishimura, S.
Nishinaka-Arai, Y.
89 - Dysregulation of DNA Methylation Involves in Progression of Myeloid Leukemia in Down Syndrome
3814 - Prognostic Significance of CXCR4 Overexpression in Pediatric Acute Myeloid Leukemia with Low-Risk: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group
4115 - Recapitulation of Transient Abnormal Myelopoiesis Using Patient Derived iPSCs
3814 - Prognostic Significance of CXCR4 Overexpression in Pediatric Acute Myeloid Leukemia with Low-Risk: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group
4115 - Recapitulation of Transient Abnormal Myelopoiesis Using Patient Derived iPSCs
Nishio, K.
Nishio, N.
1892 - Evaluation of Cytokines after Platelet-Lysate-Expanded Mesenchymal Stromal Cell Therapy for Steroid Refractory Acute Graft-Versus-Host Disease
3610 - Genetic Background of Idiopathic Bone Marrow Failure Syndromes in Children
3622 - Correction of Fanconi Anemia Mutation Using the Crispr/Cas9 System
3610 - Genetic Background of Idiopathic Bone Marrow Failure Syndromes in Children
3622 - Correction of Fanconi Anemia Mutation Using the Crispr/Cas9 System
Nishiwaki, K.
Nishiyama, A.
Nishiyama, A.
Niss, O.
Nissbeck, M.
Niswander, L. M.
Nitta, H.
Nitta, M.
Nittono, H.
Nitulescu, I.
Nityanand, S.
Niu, H.
Niu, N.
Niu, T.
264 - 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass
3774 - Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China
3774 - Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China
Niu, X.
1265 - Binding of Released Bim to Mcl-1 Is Responsible for Resistance to ABT-199 Which Can be Overcome By Combination with Daunorubicin or Cytarabine in Acute Myeloid Leukemia Cells
2469 - Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells
2469 - Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells
Nivarthi, H.
Nizzi, F.
Nloga, A. M.
Nobili, A.
Noble, C. O.
Noble, K. E.
Nobuya, H.
Nocilli, L.
Noda, M.
Noda, M.
Nodzon, L.
2941 - Sequential Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide Is a Safe and Effective Regimen for the Treatment of Previously Treated and Untreated CLL/SLL: The Hilo Trial
2945 - Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience
2945 - Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience
Noël, R.
Noellke, P.
Noerenberg*, D.
Noetzli, J.
Noetzli, L.
Nogami, A.
Nogami, K.
1076 - A Factor VIII with Site-Specific Pegylation Attenuates the Binding with Inhibitors Results in the Retention of Hemostatic Effect
1077 - ACE910 Facilitates Its Hemostatic Effect with the Lower Concentration of Factor X Than That Required for Factor VIIa-Driven Coagulation
2270 - The Acidic Region of Factor VIII Light Chain Contains the Thrombin-Binding Site(s) Responsible for the Cleavage at Arg1689
3503 - Enhanced Global Hemostatic Potentials with a Bispecific Antibody to Factors IXa and X (ACE910) in the Whole Blood By Rotation Thromboelastometry (ROTEM)
3526 - Outcome of the Japanese Immune Tolerance Induction (ITI) Registry and Predictors of Successful ITI
3565 - Anti-Factor IXa/Factor X Antibody (ACE910) Improves the Coagulation Function in Acquired Hemophilia A ex vivo
1077 - ACE910 Facilitates Its Hemostatic Effect with the Lower Concentration of Factor X Than That Required for Factor VIIa-Driven Coagulation
2270 - The Acidic Region of Factor VIII Light Chain Contains the Thrombin-Binding Site(s) Responsible for the Cleavage at Arg1689
3503 - Enhanced Global Hemostatic Potentials with a Bispecific Antibody to Factors IXa and X (ACE910) in the Whole Blood By Rotation Thromboelastometry (ROTEM)
3526 - Outcome of the Japanese Immune Tolerance Induction (ITI) Registry and Predictors of Successful ITI
3565 - Anti-Factor IXa/Factor X Antibody (ACE910) Improves the Coagulation Function in Acquired Hemophilia A ex vivo
Noguchi, S.
Noguchi, Y.
Noguchi-Sasaki, M.
Nogueira, T. C.
Noguera, M. E.
Nogueras Gonzalez, G.
598 - Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities
2943 - Ruxolitinib Reduces Cytokine/Chemokine Levels and Improves Fatigue and Chronic Lymphocytic Leukemia (CLL)-Related Symptoms in CLL Patients Not Requiring Systemic Therapy
2943 - Ruxolitinib Reduces Cytokine/Chemokine Levels and Improves Fatigue and Chronic Lymphocytic Leukemia (CLL)-Related Symptoms in CLL Patients Not Requiring Systemic Therapy
Nojima, Y.
Nolan, B.
Nolan, G. P.
906 - Mass Cytometry Analysis Dissects CRLF2-Driven Signaling Pathways in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
2534 - Role of the Histone Deacetylase Inhibitor Givinostat (ITF2357) in Treatment of CRLF2 Rearranged Acute Lymphoblastic Leukemia
2616 - Increased Frequency of Cells with Activated Ribosomal Protein S6 at Diagnosis Associates with MRD Positivity and Relapse in Childhood BCP ALL
2534 - Role of the Histone Deacetylase Inhibitor Givinostat (ITF2357) in Treatment of CRLF2 Rearranged Acute Lymphoblastic Leukemia
2616 - Increased Frequency of Cells with Activated Ribosomal Protein S6 at Diagnosis Associates with MRD Positivity and Relapse in Childhood BCP ALL
Nolasco, J.
Noll, B.
Nollet, F.
Nolte, F.
1382 - Different Impact of Expression Levels of IGFBP2 and IGFBP7 on Survival and Relapse Rate in Acute Promyelocytic Leukemia
1919 - Influence of the Insertion Site on Central Venous Catheter Related Complications in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation, High Dose Therapy or Induction Therapy for Acute Leukemia
2891 - Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment
1919 - Influence of the Insertion Site on Central Venous Catheter Related Complications in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation, High Dose Therapy or Induction Therapy for Acute Leukemia
2891 - Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment
Nolting, J.
Nomdedeu, J. F.
2511 - Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012
2514 - Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 2012
2514 - Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 2012
Nomdedeu, J. F.
Nomdedeu, M.
609 - An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)
1397 - Exploring the Expression Profile of Long Non-Coding RNA (lncRNA) in Different Acute Myeloid Leukemia (AML) Subtypes: t(8;16)(p11;p13)/MYST3-Crebbp AML Harbors a Distinctive Lncrna Signature
1672 - Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD)
1397 - Exploring the Expression Profile of Long Non-Coding RNA (lncRNA) in Different Acute Myeloid Leukemia (AML) Subtypes: t(8;16)(p11;p13)/MYST3-Crebbp AML Harbors a Distinctive Lncrna Signature
1672 - Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD)
Nomie, K.
Nomura, K.
Nonami, A.
Nooka, A. K.
3036 - A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)
3325 - The Role of County-Level Contextual Predictors in Multiple Myeloma Mortality
4202 - Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)
4241 - Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
4246 - Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)
4508 - Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States
3325 - The Role of County-Level Contextual Predictors in Multiple Myeloma Mortality
4202 - Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)
4241 - Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
4246 - Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)
4508 - Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States
Noonan, K.
3427 - Impaired Response to Influenza Vaccination in AML Patients Post-Chemotherapy Associated with a Highly Atypical B-Cell Profile
4238 - Allogeneic Myeloma GVAX with Lenalidomide Enhances Progression Free Survival through the Generation of Tumor Specific Immunity in Patients in Near Complete Remission
4238 - Allogeneic Myeloma GVAX with Lenalidomide Enhances Progression Free Survival through the Generation of Tumor Specific Immunity in Patients in Near Complete Remission
Noorani, M.
2738 - The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma
3965 - The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies
3984 - The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL
3965 - The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies
3984 - The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL
Noort, W. A.
Nooruddin, Z.
Nooti, S. K.
Norasetthada, L.
1217 - A Retrospective Multicenter Study to Evaluate the Efficacy of Rabbit Antithymocyte Globulin (rATG) Immunosuppressive Therapy As First-Line Treatment of Aplastic Anemia
1471 - Validation of German High-Grade Non-Hodgkin's Lymphoma (DSHNHL) Prognostic Model and the Impact of Treatment on Secondary Central Nervous System (CNS) Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) in a Developing Country: Report from the Nationwide Multi-Institutional Registry of Thai Lymphoma Study Group (TLSG)
2676 - Clinical Characteristics and Outcomes of Limited-Stage Primary Extranodal Versus Nodal Diffuse Large B-Cell Lymphoma (DLBCL) in Thailand: A Nationwide Multi-Institutional Registry of 920 Cases in Thailand
2712 - Consolidation Radiotherapy Improved Survival in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Nationwide Multi-Institutional Registry of 816 Cases in Thailand
3326 - Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand
1471 - Validation of German High-Grade Non-Hodgkin's Lymphoma (DSHNHL) Prognostic Model and the Impact of Treatment on Secondary Central Nervous System (CNS) Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) in a Developing Country: Report from the Nationwide Multi-Institutional Registry of Thai Lymphoma Study Group (TLSG)
2676 - Clinical Characteristics and Outcomes of Limited-Stage Primary Extranodal Versus Nodal Diffuse Large B-Cell Lymphoma (DLBCL) in Thailand: A Nationwide Multi-Institutional Registry of 920 Cases in Thailand
2712 - Consolidation Radiotherapy Improved Survival in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Nationwide Multi-Institutional Registry of 816 Cases in Thailand
3326 - Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand
Norby, C.
239 - N-Acetylcysteine Treatment in Two Patients with Relapsed Thrombotic Thrombocytopenic Purpura Increased ADAMTS13 Activity, Free Thiol Concentration in Plasma, and Inhibited Platelet Activation
972 - Evaluation of Cell Types and Morphologies in Sickle Cell Disease with an Imaging Flow Cytometer
1044 - Effect of N-Acetyl-L-Cysteine on Cysteine Redox Status in Patients with Thrombotic Thrombocytopenic Purpura: Protein Disulfide Bound Cysteine As a Biomarker of Oxidative Stress
972 - Evaluation of Cell Types and Morphologies in Sickle Cell Disease with an Imaging Flow Cytometer
1044 - Effect of N-Acetyl-L-Cysteine on Cysteine Redox Status in Patients with Thrombotic Thrombocytopenic Purpura: Protein Disulfide Bound Cysteine As a Biomarker of Oxidative Stress
Nordon, C.
Norfo, R.
Norfo, R.
Noriega, V.
Norkin, M.
1988 - Effect of Melphalan 140 Mg/m2 Versus 200 Mg/m2 on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation
3221 - Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes
3221 - Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes
Norkin, M.
Normolle, D.
Norris, M. D.
Norris, R. E.
Norster, F.
Norström, C.
Norsworthy, K. J.
Northfelt, D. W.
Norton, A.
Norton, L. J.
Norton, M.
Nosaka, K.
113 - Frequent Activating Somatic Alterations in T-Cell Receptor / NF-κb Signaling in Adult T-Cell Leukemia/Lymphoma
181 - Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma
2643 - Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Leukemia/Lymphoma
181 - Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma
2643 - Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Leukemia/Lymphoma
Nosrati, J.
1011 - Increased Alternative Macrophage-2 (M2) Polarization with Trib1 Gene over Expression in Myeloma Patients with Progressive Disease and Jak2 Inhibitors Reduce M2 Polarization
2995 - Crosslinking of Fc Gamma-Rllb and Fc Epsilon-RI Binding Peptides Inhibits Osteoclast Formation in Multiple Myeloma through Inactivation of the ITAM Signaling Pathway
2995 - Crosslinking of Fc Gamma-Rllb and Fc Epsilon-RI Binding Peptides Inhibits Osteoclast Formation in Multiple Myeloma through Inactivation of the ITAM Signaling Pathway
Notarangelo, L.
Notarangelo, L. D.
Notaro, R.
Notta, F.
Nottage, K. A.
3 - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia
2136 - The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status
2165 - Effects of Genetic Polymorphisms on Leukocyte and Neutrophil Counts and Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia
3337 - Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants
3393 - Genetic Modifiers Influencing the Development of Albuminuria in Children with Sickle Cell Anemia
2136 - The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status
2165 - Effects of Genetic Polymorphisms on Leukocyte and Neutrophil Counts and Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia
3337 - Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants
3393 - Genetic Modifiers Influencing the Development of Albuminuria in Children with Sickle Cell Anemia
Noubouossie, D.
Noumura, K.
Nouraie, M.
936 - Thrombotic Complications Are Associated with Phlebotomy Therapy in Patients with Chuvash Polycythemia
961 - Activity of RN-1, an LSD-1 Inhibitor, on Fetal Globin Expression in Sickle Mice and Sickle Erythroid Progenitors
2063 - The Prevalence of Mood and Alcohol Related Disorders within the Adult Sickle Cell Disease Population and Their Impact on Healthcare Utilization
3380 - Hydroxyurea Treatment Is Associated with Elevated Serum Erythropoietin Concentration but Suppressed Global Hypoxic Transcriptional Responses in Sickle Cell Disease
3414 - A Pilot Study of Sleep Disordered Breathing (SDB) and Nocturnal Hypoxemia in Young Adults with Sickle Cell Disease
961 - Activity of RN-1, an LSD-1 Inhibitor, on Fetal Globin Expression in Sickle Mice and Sickle Erythroid Progenitors
2063 - The Prevalence of Mood and Alcohol Related Disorders within the Adult Sickle Cell Disease Population and Their Impact on Healthcare Utilization
3380 - Hydroxyurea Treatment Is Associated with Elevated Serum Erythropoietin Concentration but Suppressed Global Hypoxic Transcriptional Responses in Sickle Cell Disease
3414 - A Pilot Study of Sleep Disordered Breathing (SDB) and Nocturnal Hypoxemia in Young Adults with Sickle Cell Disease
Nousiainen, T.
Novak, A. J.
131 - Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma
703 - VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia
2661 - The Exhausted Intratumoral T Cell Population in B-Cell Non-Hodgkin Lymphoma Is Defined By LAG-3, PD-1 and tim-3 Expression
3922 - Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma
3992 - Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era
703 - VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia
2661 - The Exhausted Intratumoral T Cell Population in B-Cell Non-Hodgkin Lymphoma Is Defined By LAG-3, PD-1 and tim-3 Expression
3922 - Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma
3992 - Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era
Novakovic, V. A.
Novelli, E. M.
Novelli, E. M.
Novelli, S.
521 - Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients
3944 - Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group
3955 - Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project
3944 - Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group
3955 - Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project
Novero, D.
2650 - De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC)
2735 - The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)
3889 - GATA-3 Expression in Peripheral T-Cell Lymphomas (PTCL): Identification of a Cut-Off and Prognostic Value in PTCL-NOS Versus Others Hystotypes
2735 - The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)
3889 - GATA-3 Expression in Peripheral T-Cell Lymphomas (PTCL): Identification of a Cut-Off and Prognostic Value in PTCL-NOS Versus Others Hystotypes
Noviello, M.
743 - HLA Loss Leukemia Relapses after Partially-Incompatible Allogeneic HSCT As a Prototypical System to Investigate Natural Killer Cell Dynamics
1929 - An Accelerated CD8+, but Not CD4+, T-Cell Reconstitution Associates with a More Favorable Outcome Following HLA-Haploidentical HSCT: Results from a Retrospective Study of the Cell Therapy and Immunobiology Working Party of the EBMT
1929 - An Accelerated CD8+, but Not CD4+, T-Cell Reconstitution Associates with a More Favorable Outcome Following HLA-Haploidentical HSCT: Results from a Retrospective Study of the Cell Therapy and Immunobiology Working Party of the EBMT
Novitzky, N.
Novo, A.
1333 - Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial
2723 - Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain
2723 - Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain
Novotny, J.
Nowak, A. A.
Nowak, D.
1382 - Different Impact of Expression Levels of IGFBP2 and IGFBP7 on Survival and Relapse Rate in Acute Promyelocytic Leukemia
2859 - Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)
2891 - Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment
4325 - Whole Genome Sequencing of Azole-Resistant Aspergillus Fumigatus Strains from Hematopoietic Stem Cell Recipients Identifies Candidate Molecular Targets Potentially Implicated in Novel Resistance Mediating Mechanisms - First Results
2859 - Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)
2891 - Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment
4325 - Whole Genome Sequencing of Azole-Resistant Aspergillus Fumigatus Strains from Hematopoietic Stem Cell Recipients Identifies Candidate Molecular Targets Potentially Implicated in Novel Resistance Mediating Mechanisms - First Results
Nowak, E.
Nowak, M.
Nowak, N. J.
Nowak, V.
1382 - Different Impact of Expression Levels of IGFBP2 and IGFBP7 on Survival and Relapse Rate in Acute Promyelocytic Leukemia
2859 - Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)
2891 - Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment
4325 - Whole Genome Sequencing of Azole-Resistant Aspergillus Fumigatus Strains from Hematopoietic Stem Cell Recipients Identifies Candidate Molecular Targets Potentially Implicated in Novel Resistance Mediating Mechanisms - First Results
2859 - Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)
2891 - Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment
4325 - Whole Genome Sequencing of Azole-Resistant Aspergillus Fumigatus Strains from Hematopoietic Stem Cell Recipients Identifies Candidate Molecular Targets Potentially Implicated in Novel Resistance Mediating Mechanisms - First Results
Nowak-Gottl, U.
Nowak-Göttl, U.
Nowakowska, P.
Nowakowski, G. S.
131 - Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma
813 - Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)
1456 - Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era
2490 - Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis
2683 - Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy
3730 - Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients
3885 - Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma
3992 - Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era
813 - Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)
1456 - Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era
2490 - Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis
2683 - Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy
3730 - Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients
3885 - Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma
3992 - Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era
Nowill, A.
Nowotny, C.
Noxon, V.
Noy, A.
342 - Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R
1498 - Feasibility of Interim PET-Adapted Therapy in HIV-Positive Patients with Advanced Hodgkin Lymphoma (HL): Sub-Analysis of SWOG S0816 Phase 2 Trial
1526 - AMC-085: A Pilot Trial of AVD and Brentuximab Vedotin in the Upfront Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma. A Trial of the AIDS Malignancy Consortium
2668 - Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay
2691 - Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma
4383 - A Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Hodgkin Lymphoma
1498 - Feasibility of Interim PET-Adapted Therapy in HIV-Positive Patients with Advanced Hodgkin Lymphoma (HL): Sub-Analysis of SWOG S0816 Phase 2 Trial
1526 - AMC-085: A Pilot Trial of AVD and Brentuximab Vedotin in the Upfront Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma. A Trial of the AIDS Malignancy Consortium
2668 - Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay
2691 - Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma
4383 - A Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Hodgkin Lymphoma
Noyan, F.
Ntambi, J.
Ntavlouros, P.
Ntoufa, S.
365 - Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia
1712 - ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome
4129 - Chystallographic Evidence of Autologous Recognition By a Clonotypic B Cell Receptor in Chronic Lymphocytic Leukemia
4142 - Tp63 Contributes to the Apoptosis Resistant Phenotype in Aggressive Chronic Lymphocytic Leukemia
1712 - ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome
4129 - Chystallographic Evidence of Autologous Recognition By a Clonotypic B Cell Receptor in Chronic Lymphocytic Leukemia
4142 - Tp63 Contributes to the Apoptosis Resistant Phenotype in Aggressive Chronic Lymphocytic Leukemia
Ntziachristos, P.
Nuamah, R.
Nudelman, O.
Nugent, D. J.
Nugent, D. J.
Nukaya, I.
Numbenjapon, T.
1471 - Validation of German High-Grade Non-Hodgkin's Lymphoma (DSHNHL) Prognostic Model and the Impact of Treatment on Secondary Central Nervous System (CNS) Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) in a Developing Country: Report from the Nationwide Multi-Institutional Registry of Thai Lymphoma Study Group (TLSG)
2676 - Clinical Characteristics and Outcomes of Limited-Stage Primary Extranodal Versus Nodal Diffuse Large B-Cell Lymphoma (DLBCL) in Thailand: A Nationwide Multi-Institutional Registry of 920 Cases in Thailand
2712 - Consolidation Radiotherapy Improved Survival in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Nationwide Multi-Institutional Registry of 816 Cases in Thailand
3326 - Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand
2676 - Clinical Characteristics and Outcomes of Limited-Stage Primary Extranodal Versus Nodal Diffuse Large B-Cell Lymphoma (DLBCL) in Thailand: A Nationwide Multi-Institutional Registry of 920 Cases in Thailand
2712 - Consolidation Radiotherapy Improved Survival in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Nationwide Multi-Institutional Registry of 816 Cases in Thailand
3326 - Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand
Nunez, L. D.
Nunez-Cruz, S.
Nunn, M. A.
Nunnery, S. E.
Nunomura, T.
Nuovo, G. J.
Nurieva, R.
Nussenblatt, R. B.
Nuzzo, S.
Nwankwo, J. O.
Nwosu-Iheme, A.
Nyirenda, T.